Omeros’ (OMER) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Rodman & Renshaw started coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 3.1 %

NASDAQ OMER opened at $9.18 on Thursday. The company has a 50 day moving average price of $9.25 and a two-hundred day moving average price of $5.96. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60. The stock has a market capitalization of $531.98 million, a PE ratio of -3.97 and a beta of 2.01.

Institutional Trading of Omeros

Several institutional investors have recently made changes to their positions in the business. MML Investors Services LLC raised its position in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. State Street Corp raised its holdings in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,000 shares during the period. Rhumbline Advisers boosted its stake in Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 6,435 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.